Orion Oyj (ORNBV.HE) Osake Kurssi
Orion Oyj Kurssi
Liikevaihto on kasvanut 10,0 % vuodessa viimeisten 19 vuoden aikana 1,89 Mrd. EUR:een. Osakekohtainen tulos on kasvanut 11,2 % vuodessa viimeisten 19 vuoden aikana. Orion Oyjn nettomarginaali on nyt 26,5 %, noussut 18,6 %:sta muutama vuosi sitten. Orion Oyjn osinkotuotto on tällä hetkellä noin 1,87 %. Jakosuhde on noin 46 % tuloksesta. Osinko on kasvanut 2,8 % vuodessa viimeisten 18 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 76,50 EUR, eli ali nykyhintaa 12,8 %. 15 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
Orion Oyj osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Orion Oyj liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Orion Oyj -osakkeesta
The business model of Orion Oyj revolves around the development, manufacturing, and marketing of pharmaceuticals and diagnostic tests. Orion Oyj specializes in various therapeutic areas including neurological disorders, respiratory diseases, and oncology. They focus on research and development of new innovative drugs to address unmet medical needs. By combining expertise in pharmaceuticals and diagnostics, Orion Oyj aims to provide effective and safe treatment options for patients globally. With its strong commitment to scientific excellence and continuous innovation, Orion Oyj strives to improve the quality of life for individuals affected by various diseases.
Orion Oyj is primarily active in the pharmaceutical industry. As a leading Finnish pharmaceutical company, Orion Oyj specializes in the development, manufacturing, and marketing of innovative pharmaceuticals and active pharmaceutical ingredients. With a strategic focus on neurological and respiratory diseases, Orion Oyj aims to improve people's well-being and contribute to medical advancements. Not only does Orion Oyj offer a diverse range of products in these therapeutic areas, but it also operates globally, exporting its pharmaceuticals to numerous countries. This commitment to the pharmaceutical industry makes Orion Oyj a key player in the healthcare sector.
The main competitors of Orion Oyj in the market include Novartis AG, Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc.
Orion Oyj is a renowned Finnish pharmaceutical company. Founded in 1917, Orion has a rich history of over a century in the industry. The company focuses on developing innovative pharmaceuticals and diagnostic tests, ensuring the well-being of individuals globally. Throughout its existence, Orion Oyj has grown to become one of the leading pharmaceutical companies in Northern Europe, with a strong emphasis on research and development. With a diverse product portfolio that includes prescription medicines, generic drugs, and active pharmaceutical ingredients, Orion Oyj aims to improve people's lives and provide effective healthcare solutions.
Orion Oyj has achieved significant milestones throughout its history. The Finnish pharmaceutical company has successfully developed and launched various innovative drugs, contributing to advancements in healthcare. Notably, Orion Oyj achieved a major milestone with the development and commercialization of Stalevo, a medication for the treatment of Parkinson's disease. The company also made significant progress in the field of oncology with the launch of Simdax, a drug used to improve cardiac function in patients with acute decompensated heart failure. Additionally, Orion Oyj has expanded its global presence through strategic collaborations and acquisitions, further solidifying its position as a leading player in the pharmaceutical industry.
Orion Oyj is primarily present in Finland, where it is headquartered. As a Finnish pharmaceutical company, Orion Oyj operates mainly in the Nordic countries, including Sweden, Norway, Denmark, and Iceland. However, the company's reach extends beyond the Nordic region, with a presence in several other countries and regions worldwide. This includes markets in Europe, such as the United Kingdom, Germany, France, and Spain. Orion Oyj also has a global presence with its products being exported to numerous countries in Asia, Africa, the Americas, and Australia.
Orion Oyj represents a strong set of values and corporate philosophy. As a leading pharmaceutical company based in Finland, Orion Oyj is committed to improving people's well-being through the development and commercialization of innovative medicines and treatments. The company's core values include professionalism, reliability, and integrity. Orion Oyj aims to provide effective and safe healthcare solutions while maintaining a high ethical standard in all its operations. With a focus on research and development, Orion Oyj strives to contribute to medical advancements and enhance patient care worldwide. As a result, Orion Oyj maintains a strong reputation as a trustworthy and responsible pharmaceutical company.
Analyytikot asettavat tällä hetkellä Orion Oyj-osakkeelle keskimääräisen tavoitehinnan 73,59 EUR (mediaani: 76,50 EUR), mikä merkitsee −16,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 15 analyytikkoarvioon.
15 analyytikkoa arvioi tällä hetkellä Orion Oyj-osaketta: 11 suosittaa ostoa, 3 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Orion Oyj-yhtiöltä 2,11 Mrd. EUR liikevaihtoa ja 4,07 EUR osakekohtaista tulosta.
Orion Oyj-osake (ORNBV.HE) on listattuna 9 pörssissä, muun muassa: London (0M2O.L), SIX (Zürich) (ORNBV.SW), Frankfurt (OFK.F), München (OFK.MU), Düsseldorf (OFK.DU).
Orion Oyj is a Finnish company that was founded in 1917 and is now considered a leading manufacturer of pharmaceuticals, diagnostics, and animal health products in Northern and Central Europe. The company is divided into three divisions: human pharmaceuticals, specialty pharmaceuticals, and animal health. The human pharmaceuticals division is the main source of revenue for the company and offers a wide range of prescription drugs for various therapy areas such as neurology, oncology, urology, gastroenterology, and cardiology. Orion Oyj continuously develops innovative products and technologies for the healthcare industry and has had numerous successful product launches in recent years. The specialty pharmaceuticals division specializes in manufacturing medications for rare diseases. Among other products, the company manufactures treatments for Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), and Parkinson's disease. The third business area is animal health. Orion Oyj offers a wide range of medications for livestock and pets. The company is a leader in the production of free-range pig vaccines, which are in high demand, particularly in Northern Europe and the Baltic states. Orion Oyj is headquartered in Espoo, Finland, and employs over 3,000 people worldwide. The company is also listed on the Finnish stock exchange and had a revenue of approximately 1.1 billion euros in 2019. Orion Oyj has a clear strategy regarding its products and services. It focuses on strong partnerships and investments in research and development as well as production. The company aims to strengthen its position as a market leader in Northern Europe and the specialized pharmaceutical industry worldwide. Additionally, Orion Oyj has a strong local presence in many European countries and operates production facilities in Finland and Germany. The high standards of product quality and production safety are supported by Orion Oyj's quality management system. As part of its international expansion, the company has also expanded into other markets, such as South America. In doing so, the company prioritizes sustainability and ethics. It aims to promote best practices in ecological, social, and community matters both within and outside the company. Overall, Orion Oyj is a company that offers a wide range of products and services in the field of human pharmaceuticals, specialty pharmaceuticals, and animal health. With its strong partnerships, investments in research and development, and a clear focus on the highest product quality and production safety, the company is well-equipped to expand its position as a leading provider in Northern Europe and the specialized pharmaceutical industry worldwide.
odotettu liikevaihto Orion Oyj on 2,11 Mrd. EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Orion Oyj on 572,94 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Orion Oyj:n hinta-voitto-suhde (P/E) on tällä hetkellä 21,55. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Orion Oyj-osakkeen arvostusta.
Orion Oyj:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,85. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Orion Oyj-osakkeen arvostuskennuslukuna.
Orion Oyj:n Eulpool-laatuscore on 8/10.
Orion Oyj:n ISIN on FI0009014377. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Orion Oyj:n WKN on A0J3QM. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Orion Oyj:n ticker on ORNBV.HE. Tämä pörssinoteeraus käytetään Orion Oyj-osakkeiden kauppaan pörssissä.
Orion Oyj osake
Kaikki tunnusluvut ja syvällinen analyysi Orion Oyj:sta
Meidän osakeanalyysimme Orion Oyj-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Orion Oyj:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: